 Angiotensin Receptor Antagonists
"Angiotensin Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.
| Descriptor ID |
D057911
|
| MeSH Number(s) |
D27.505.519.162
|
| Concept/Terms |
Angiotensin Receptor Antagonists- Angiotensin Receptor Antagonists
- Antagonists, Angiotensin Receptor
- Receptor Antagonists, Angiotensin
- Angiotensin Receptor Blockers
- Receptor Blockers, Angiotensin
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin Receptor Antagonists".
This graph shows the total number of publications written about "Angiotensin Receptor Antagonists" by people in this website by year, and whether "Angiotensin Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 1996 | 1 | 1 | 2 | | 1997 | 1 | 0 | 1 | | 2001 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2006 | 0 | 2 | 2 | | 2008 | 0 | 1 | 1 | | 2010 | 0 | 2 | 2 | | 2011 | 1 | 1 | 2 | | 2013 | 0 | 2 | 2 | | 2015 | 1 | 2 | 3 | | 2016 | 3 | 1 | 4 | | 2017 | 3 | 0 | 3 | | 2018 | 4 | 2 | 6 | | 2019 | 0 | 2 | 2 | | 2020 | 2 | 1 | 3 | | 2021 | 3 | 9 | 12 | | 2022 | 0 | 6 | 6 | | 2023 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Angiotensin Receptor Antagonists" by people in Profiles.
-
Lu Y, Liu Y, Dhingra LS, Caraballo C, Mahajan S, Massey D, Spatz ES, Sharma R, Rodriguez F, Watson KE, Masoudi FA, Krumholz HM. National Trends in Racial and Ethnic Disparities in Use of Recommended Therapies in Adults with Atherosclerotic Cardiovascular Disease, 1999-2020. JAMA Netw Open. 2023 12 01; 6(12):e2345964.
-
Bhatt AS, Fonarow GC, Greene SJ, Holmes DN, Alhanti B, Devore AD, Butler J, Heidenreich PA, Huang JC, Kittleson MM, Linganathan K, Joyntmaddox KE, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Vaduganathan M. Medical Therapy Before, During and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: Get With The Guidelines - Heart Failure Registry. J Card Fail. 2024 Feb; 30(2):319-328.
-
Pierce JB, Blumer V, Choi S, Hardy NC, Greiner MA, Carnicelli AP, Shen X, Lippmann SJ, Peterson PN, Allen LA, Fonarow GC, Mentz RJ, Greene SJ, O'Brien EC. Comparative Outcomes of Sacubitril/Valsartan Use After Hospitalization for Heart Failure Among Medicare Beneficiaries Na?ve to Renin-Angiotensin System Inhibitors. Am J Cardiol. 2023 10 01; 204:151-158.
-
Ambardekar AV, El Rafei A. Guideline-Directed Medical Therapy in?Heart?Failure: The Treatment Is Not Worse Than the Disease. JACC Heart Fail. 2023 04; 11(4):437-439.
-
Smith SM, Winterstein AG, Gurka MJ, Walsh MG, Keshwani S, Libby AM, Hogan WR, Pepine CJ, Cooper-DeHoff RM. Initial Antihypertensive Regimens in Newly Treated Patients: Real World Evidence From the OneFlorida+ Clinical Research Network. J Am Heart Assoc. 2023 01 03; 12(1):e026652.
-
Pierce JB, Li Z, Greiner MA, Lippmann SJ, Hardy NC, Shen X, Stampehl M, Mentz RJ, Allen LA, Peterson PN, Fonarow GC, O'Brien EC, Greene SJ. Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry. Circ Heart Fail. 2023 01; 16(1):e010176.
-
Wise RA, Holbrook JT, Brown RH, Criner GJ, Dransfield MT, He J, Henderson RJ, Kaminsky DA, Kaner RJ, Lazarus SC, Make BJ, McCormack MC, Neptune ER, Que LG. Clinical Trial of Losartan for Pulmonary Emphysema: Pulmonary Trials Cooperative Losartan Effects on Emphysema Progression Clinical Trial. Am J Respir Crit Care Med. 2022 10 01; 206(7):838-845.
-
Granger BB, Kaltenbach LA, Fonarow GC, Allen LA, Lanfear DE, Albert NM, Al-Khalidi HR, Butler J, Cooper LB, Dewald T, Felker GM, Heidenreich P, Kottam A, Lewis EF, Pi?a IL, Yancy CW, Granger CB, Hernandez AF, Devore AD. Health System-Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: Results From the CONNECT-HF Trial. J Card Fail. 2022 08; 28(8):1355-1361.
-
Valente R, Crippa S, Arnelo U, Vanella G, Zerboni G, Zarantonello L, Fogliati A, Arcidiacono PG, Vujasinovic M, Lohr JM, Falconi M, Capurso G, Del Chiaro M. The use of ace inhibitors influences the risk of progression of BD-IPMNs under follow-up. Pancreatology. 2022 May; 22(4):516-524.
-
Thomas SA, Puskarich M, Pulia MS, Meltzer AC, Camargo CA, Courtney DM, Nordenholz KE, Kline JA, Kabrhel C. Association Between Baseline Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin?Receptor Blockers and Death Among Patients Tested for COVID-19. J Clin Pharmacol. 2022 06; 62(6):777-782.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|